Drugs / HCVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04318379 | Apr 2021 → Feb 2023 | chronic hepatitis C virus infection | GeneCure Biotechnologies | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04318379 ↗ |
| Modality | Vaccine | “HCVax™ vaccine” NCT04318379 ↗ |
| Route | Subcutaneous | “through subcutaneous route” NCT04318379 ↗ |